Slingshot members are tracking this event:

Exelixis' cabozantinib NDA for advanced kidney cancer gets Priority Review, action date (PDUFA) set for June 22

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Cabozantinib is currently marketed as COMETRIQ in the US. 
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cabozantinib, Renal Cell Carcinoma, Priority Review